CalciMedica (NASDAQ:CALC) Earns Buy Rating from HC Wainwright

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $16.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 380.48% from the stock’s current price.

CalciMedica Stock Performance

Shares of CALC opened at $3.33 on Thursday. The firm has a fifty day moving average of $4.04 and a 200-day moving average of $4.54. The company has a market cap of $35.80 million, a price-to-earnings ratio of -3.08 and a beta of 1.30. CalciMedica has a 1 year low of $2.68 and a 1 year high of $8.38.

Insider Activity at CalciMedica

In related news, Director Robert N. Wilson purchased 54,000 shares of CalciMedica stock in a transaction dated Friday, August 23rd. The stock was bought at an average cost of $3.72 per share, with a total value of $200,880.00. Following the purchase, the director now owns 364,196 shares in the company, valued at approximately $1,354,809.12. The trade was a 17.41 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Fred A. Middleton acquired 87,744 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was bought at an average price of $3.75 per share, with a total value of $329,040.00. Following the completion of the acquisition, the director now directly owns 814,300 shares of the company’s stock, valued at approximately $3,053,625. This represents a 12.08 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 312,944 shares of company stock worth $1,172,910 in the last three months. 41.55% of the stock is owned by company insiders.

Institutional Investors Weigh In On CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Atria Investments Inc increased its position in CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,503 shares of the company’s stock after buying an additional 15,296 shares during the quarter. Atria Investments Inc owned about 0.25% of CalciMedica worth $117,000 at the end of the most recent reporting period.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.